Related Experiment Video
Updated: Aug 25, 2026
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins for primary and secondary prevention of coronary heart disease. A scientific review
António Vaz Carneiro1, João Costa, Margarida Borges
1Centro de Estudos de Medicina Baseada na Evidência Faculdade de Medicina de Lisboa, Lisboa, Portugal.
Insights
Statins effectively lower cholesterol, reducing cardiovascular disease and coronary heart disease (CHD) events in both primary and secondary prevention. Evidence from randomized controlled trials supports their use for improving patient outcomes and reducing mortality.
Area of Science:
- Cardiology
- Preventive Medicine
- Pharmacology
Background:
- Cardiovascular disease (CVD) prevalence increases with age, with elevated serum lipids, particularly cholesterol, being a major risk factor.
- Hypercholesterolemia is strongly linked to coronary heart disease (CHD), and its management significantly reduces cardiovascular events and mortality.
- Statins are a key therapeutic class for managing dyslipidemia and preventing cardiovascular events.
Purpose of the Study:
- To review and discuss the scientific evidence for using statins in primary and secondary prevention of coronary heart disease (CHD).
- To synthesize findings from large randomized controlled trials (RCTs) and meta-analyses published within the last decade.
- To provide evidence-based recommendations for patient selection for statin therapy.
Main Methods:
- Systematic review and discussion of large randomized controlled trials (RCTs) focusing on clinically relevant outcomes (mortality, morbidity, event rates).
- Inclusion of meta-analyses and systematic reviews of RCTs published within the last 5 years.
- Selection of evidence from secondary scientific sources.
Main Results:
- Lowering total cholesterol and low-density lipoprotein (LDL) cholesterol, while increasing high-density lipoprotein (HDL) cholesterol, diminishes coronary event rates and cardiovascular mortality.
- Statins demonstrate benefits in both primary prevention (individuals without known CHD) and secondary prevention (individuals with established CHD).
- Evidence supports the efficacy of statins in reducing cardiovascular events and mortality across diverse patient populations.
Conclusions:
- Statins are a cornerstone in the primary and secondary prevention of coronary heart disease (CHD).
- Evidence from robust clinical trials supports the use of statins to reduce cardiovascular morbidity and mortality.
- Practical, evidence-based recommendations for patient selection for statin therapy are crucial for optimizing outcomes.
Abstract:
Cardiovascular disease has an elevated prevalence in the general population, with increasing incidence with advancing age. Epidemiological studies clearly show that higher concentrations of serum lipids (especially cholesterol) constitute a major individual risk factor, and that their treatment reduces the incidence of cardiovascular disease, especially coronary heart disease (CHD). The best evidence supporting the importance of hypercholesterolemia as a major risk factor for CHD arises from large randomized controlled trials (RCTs), which show that by lowering total cholesterol and low-density lipoprotein concentrations, and increasing high-density lipoprotein concentrations, coronary event rates and cardiovascular mortality are diminished. Also, hyperlipidemia is frequently found in patients suffering from premature CHD and, in most cases, has a familial genetic component. The benefit from lowering cholesterol is found in primary prevention (patients with hypercholesterolemia but no known CHD), as well as in secondary prevention (patients with known CHD, in whom the aim is to improve prognosis). The main objective of this paper is to present and discuss the most valid, important and applicable scientific evidence on the primary and secondary prevention of coronary heart disease using statins. We have based our discussion on large RCTs that studied clinically relevant outcomes (mortality, morbidity, event rates, etc.), published over the last 10 years, as well as on systematic reviews and/or meta-analyses of RCTs published over the last 5 years. Both types of evidence were selected from secondary scientific sources. We conclude with practical evidence-based recommendations on the selection of patients for primary and secondary prevention with statins.
Related Concept Videos
01:26Atherosclerosis III: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Coronary Artery Disease IV: Preventive Measures
01:27Coronary Artery Disease V: Interprofessional Care
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications